METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PATIENTS HAVING MULTIPLE MYELOMA THAT RESPOND TO STATIN THERAPY

摘要

A method of determining whether a sample or cancer cell from a subject is likely to be sensitive to a treatment that depletes mevalonate such as statin treatment comprising: determining whether the sample or cancer cell has a dysregulated mevalonate pathway, for example by determining a level of gene expression activity or gene copy number of one or more genes listed in Figure 4 and/or in Tables 3, 4, 5 and/or 6. Dysregulation of the mevalonate pathway and/or expression level patterns that are similar to statin sensitive cells is indicative that the cancer cell is likely sensitive to for example statin treatment.